Loading...
Market
Which country will be the first to start commercial sale of lenacapavir by March 31, 2025?
2
Resolution / Starting Odds
India • 25%
South Africa • 25%
Brazil • 25%
Other • 25%
Sales reports from Gilead Sciences or the generic manufacturers
Story
Gilead Signs Royalty-Free Deals with Six Generics for Investigational HIV Drug Lenacapavir in 120 Countries
Oct 2, 2024, 01:35 PM
Gilead Sciences has signed non-exclusive, royalty-free voluntary licensing agreements with six generic pharmaceutical manufacturers, including Dr. Reddy's Laboratories and Hetero, to enable access to its investigational HIV prevention medication, lenacapavir, across 120 high-incidence, resource-limited countries. Lenacapavir, pending regulatory approval, is a twice-yearly injectable drug used for HIV-1 prevention and treatment in heavily treatment-experienced adults. The agreements aim to increase global access to this groundbreaking medication, accelerating the global HIV response.
View original story
Similar markets
United States • 25%
European Union • 25%
South Africa • 25%
Other • 25%
India • 25%
South Africa • 25%
Brazil • 25%
Other • 25%
North America • 25%
Europe • 25%
Africa • 25%
Asia • 25%
United States • 25%
South Africa • 25%
India • 25%
Other • 25%
USA • 25%
UK • 25%
South Africa • 25%
Other • 25%
Sub-Saharan Africa • 25%
Southeast Asia • 25%
South America • 25%
Other • 25%
Dr. Reddy's Laboratories • 25%
Cipla • 25%
Mylan • 25%
Other • 25%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61+ • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Other • 25%